Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2018 5
2019 5
2020 2
2021 6
2022 6
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50.
Takei S, Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Katayama Y, Nishioka N, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K. Takei S, et al. Among authors: tanimura k. Front Immunol. 2024 Feb 23;15:1348034. doi: 10.3389/fimmu.2024.1348034. eCollection 2024. Front Immunol. 2024. PMID: 38464519 Free PMC article.
Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study.
Katayama Y, Yamada T, Morimoto K, Fujii H, Morita S, Tanimura K, Takeda T, Okada A, Shiotsu S, Chihara Y, Hiranuma O, Yamada T, Ota T, Harada T, Hasegawa I, Iwasaku M, Tokuda S, Tanaka N, Miyagawa-Hayashino A, Takayama K. Katayama Y, et al. Among authors: tanimura k. JTO Clin Res Rep. 2024 Jan 30;5(3):100644. doi: 10.1016/j.jtocrr.2024.100644. eCollection 2024 Mar. JTO Clin Res Rep. 2024. PMID: 38444594 Free PMC article.
Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.
Yoshimura A, Takeda T, Kataoka N, Tanimura K, Fukui M, Chihara Y, Takei S, Kawachi H, Nakanishi K, Yamanaka Y, Tamiya N, Honda R, Okura N, Yamada T, Uryu K, Murai J, Shiotsu S, Yoshioka H, Yamada T, Kurata T, Takayama K. Yoshimura A, et al. Among authors: tanimura k. Front Oncol. 2024 Jan 26;14:1303543. doi: 10.3389/fonc.2024.1303543. eCollection 2024. Front Oncol. 2024. PMID: 38344209 Free PMC article.
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status.
Morimoto K, Yamada T, Kawachi H, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Nishioka N, Katayama Y, Iwasaku M, Tokuda S, Kijima T, Takayama K. Morimoto K, et al. Among authors: tanimura k. Target Oncol. 2023 Nov;18(6):915-925. doi: 10.1007/s11523-023-01012-1. Epub 2023 Oct 30. Target Oncol. 2023. PMID: 37902896
First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.
Tanimura K, Takeda T, Kataoka N, Yoshimura A, Nakanishi K, Yamanaka Y, Yoshioka H, Honda R, Uryu K, Fukui M, Chihara Y, Takei S, Kawachi H, Yamada T, Tamiya N, Okura N, Yamada T, Murai J, Shiotsu S, Kurata T, Takayama K. Tanimura K, et al. Cancers (Basel). 2023 Oct 14;15(20):4988. doi: 10.3390/cancers15204988. Cancers (Basel). 2023. PMID: 37894357 Free PMC article.
Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study.
Tanimura K, Takeda T, Yoshimura A, Honda R, Goda S, Shiotsu S, Fukui M, Chihara Y, Uryu K, Takei S, Katayama Y, Hibino M, Yamada T, Takayama K. Tanimura K, et al. Cancers (Basel). 2023 Sep 1;15(17):4358. doi: 10.3390/cancers15174358. Cancers (Basel). 2023. PMID: 37686634 Free PMC article.
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Ishida M, Katayama Y, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K. Kawachi H, et al. Among authors: tanimura k. JAMA Netw Open. 2023 Jul 3;6(7):e2322915. doi: 10.1001/jamanetworkopen.2023.22915. JAMA Netw Open. 2023. PMID: 37432682 Free PMC article.
TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study.
Katayama Y, Yamada T, Morimoto K, Fujii H, Morita S, Tanimura K, Takeda T, Okada A, Shiotsu S, Chihara Y, Hiranuma O, Yamada T, Ota T, Harada T, Hasegawa I, Yoshimura A, Iwasaku M, Tokuda S, Kim YH, Takayama K. Katayama Y, et al. Among authors: tanimura k. JTO Clin Res Rep. 2023 Mar 7;4(4):100494. doi: 10.1016/j.jtocrr.2023.100494. eCollection 2023 Apr. JTO Clin Res Rep. 2023. PMID: 37020925 Free PMC article.
36 results